PD37-04 LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE (TU) IN HYPOGONADAL MEN WITH CARDIOVASCULAR DISEASES (CVD): OBSERVATIONAL DATA FROM A REGISTRY STUDY

Abstract

You have accessJournal of UrologySexual Function/Dysfunction/Andrology: Medical and Non-Surgical Therapy I1 Apr 2015PD37-04 LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE (TU) IN HYPOGONADAL MEN WITH CARDIOVASCULAR DISEASES (CVD): OBSERVATIONAL DATA FROM A REGISTRY STUDY Ahmad Haider, Karim Sultan Haider, Gheorghe Doros, and Abdulmaged Traish Ahmad HaiderAhmad Haider More articles by this author , Karim Sultan HaiderKarim Sultan Haider More articles by this author , Gheorghe DorosGheorghe Doros More articles by this author , and Abdulmaged TraishAbdulmaged Traish More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2266AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Hypogonadism is associated with cardiometabolic risk. Studies suggest that hypogonadism increases the risk of all-cause and cardiovascular mortality. While some short-term studies have been performed in men with CVD, there are no data on long-term effects of testosterone therapy in men with CVD. METHODS In a prospective, cumulative, observational registry study from a single urologist's office, 340 men with testosterone ≤350 ng/dl (12.1 nmol/L) received TU injections for up to 6 years. In this subgroup analysis, 68 men with a previous diagnosis of coronary artery disease (CAD; n=40) and/or a history of myocardial infarction (MI; n=40) and/or stroke (n=6) were analyzed. RESULTS Mean age was 60.76±4.94 years. All men except four were obese. 68 men were included for 3 years, 59 for 4 years, 54 for 5 years, 44 for 6 years, and 28 for 7 years. Declining numbers reflect the nature of the registry but not drop-out rates. Weight (kg) decreased from 115.07±13.71 to 90.79±8.92. Waist circumference (cm) decreased from 112.07±7.97 to 99.14±6.53. BMI decreased from 37.27±4.45 to 29.58±3 (p<0.0001 for all). Mean weight loss was 18.75%. Fasting glucose decreased from 108.74±17.08 to 96.14±2.01 mg/dl, HbA1c from 7.79±1.18 to 5.86±0.49% (p<0.0001 for both). Total cholesterol decreased from 304.66±34.09 to 187.75±7.6, LDL from 184.28±37.51 to 120.64±22.29, triglycerides from 308.38±56.3 to 187.04±7.65 mg/dl (p<0.0001 for all). HDL increased slightly. The total cholesterol:HDL ratio declined from 5.16±1.55 to 2.97±0.77 (p<0.0001). Systolic BP decreased from 167.82±11.01 to 142.39±9.54, diastolic BP from 102.28±8.23 to 80.07±7.13 mmHg (p<0.0001 for both). Pulse pressure declined from 65.54±5.24 to 62.32±5.15 (p<0.0001). In no patient testosterone was discontinued or interrupted. There were no major cardiovascular events during the observation time. CONCLUSIONS Testosterone treatment in hypogonadal men with CVD was well tolerated and resulted in significant and sustained improvements of cardiometabolic risk factors. Medication adherence was excellent. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e771 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ahmad Haider More articles by this author Karim Sultan Haider More articles by this author Gheorghe Doros More articles by this author Abdulmaged Traish More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...